A comprehensive anticancer molecular study for genistein the promising anticancer drug
AbstractObjective Genistein a potent isoflavonoid isolated from dietary soybean with a wide range of biological and therapeutic activities, particularly, in cancer prevention. The molecular mechanism that explains this powerful chemopreventive activity is still not fully understood. The study designed to give a clear and complete picture about this mechanism using a flow cytometry analysis and a quantitative real-time PCR to investigate 16 gene families for 1023 genes.Methods Human cervical cancer cells were treated with genistein IC 50 for 48 h. Cell-cycle arrest and apoptosis induction were investigated using flow cytometry analysis. The high-throughput quantitative PCR array was used to explore the up- and down-regulated genes affected by the treatment.Results The quantitative real-time PCR analysis demonstrated the up- and down-regulation to 11 cancer-related gene families due to genistein treatment. Most of the up- and down-regulated genes have a role in cell proliferation, DNA replication and cell cycle progress. These findings were in harmony with the flow cytometry analysis in which a significant increase was manifested in the apoptotic cells (P < 0.05) of the treated cell cultures (18.34%) when compared with untreated cell cultures (5.7%).Conclusion The results highly pointed on the importance of genistein as promising anticancer drug. A comprehensive map regarding the anticancer molecular mechanism of this natural compound was given and many new therapeutic targets to control cancer development were uncovered.Keywords genistein, anticancer, cervical cancer, flavonoids
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.Copyright of the manuscripts is retained by the authors. Authors grant Nab'a Al-Hayat Foundation for Medical Sciences and Health Care - Press, an exclusive unlimited license to publish the article under a Creative Commons Attribution-NonCommercial 3.0 and identify Nab'a Al-Hayat Foundation for Medical Sciences and Health Care - Press as the sole publisher. Submission of an article for publication implies the authors’ consent to publication under the applicable Creative Commons license and the terms and conditions of the Publisher’s Licensing Agreement.